NCT03523351: Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

NCT03523351
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patient must have high risk bone metastases that are asymptomatic or minimally symptomatic
Exclusions: Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03523351

Comments are closed.

Up ↑